News | May 22, 2026
Aurobindo Pharma Q4 FY26 revenue rises 5.6% to Rs. 8,853 crore
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval
The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)
The development comes as stroke remains one of the world’s biggest health threats
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
Subscribe To Our Newsletter & Stay Updated
